about
Pirfenidone in the treatment of idiopathic pulmonary fibrosis: an evidence-based review of its place in therapyPharmacological Treatment of Idiopathic Pulmonary Fibrosis: Current Approaches, Unsolved Issues, and Future PerspectivesPirfenidone for Idiopathic Pulmonary Fibrosis: A Systematic Review and Meta-AnalysisClinical trials of investigational agents for IPF: a review of a Cochrane reportEfficacy and safety of pirfenidone for idiopathic pulmonary fibrosisIdiopathic Pulmonary Fibrosis: Treatment and PrognosisUpdate on therapeutic management of idiopathic pulmonary fibrosisPotential role of the inflammasome-derived inflammatory cytokines in pulmonary fibrosisAdverse events of pirfenidone for the treatment of pulmonary fibrosis: a meta-analysis of randomized controlled trialsFibrocytes and the pathogenesis of diffuse parenchymal lung disease.Pirfenidone for idiopathic pulmonary fibrosis: analysis of pooled data from three multinational phase 3 trials.Update in diffuse parenchymal lung disease 2011Comprehensive assessment of the long-term safety of pirfenidone in patients with idiopathic pulmonary fibrosisIncreased incidence of autoimmune markers in patients with combined pulmonary fibrosis and emphysema.Treatment patterns, resource use and costs of idiopathic pulmonary fibrosis in Spain--results of a Delphi Panel.Pharmacologic therapies for idiopathic pulmonary fibrosis, past and future.Current and novel drug therapies for idiopathic pulmonary fibrosis.Cathepsin K Contributes to Cavitation and Collagen Turnover in Pulmonary TuberculosisThe role of pirfenidone in the treatment of idiopathic pulmonary fibrosis.Recommendations on treatment for IPF.Pirfenidone for the treatment of Hermansky-Pudlak syndrome pulmonary fibrosisOccurrence of idiopathic pulmonary fibrosis during immunosuppressive treatment: a case report.Microarray profiling reveals suppressed interferon stimulated gene program in fibroblasts from scleroderma-associated interstitial lung disease.Pirfenidone treatment in idiopathic pulmonary fibrosis: nationwide Danish results.The diagnosis and treatment of idiopathic pulmonary fibrosisThe treatment of idiopathic pulmonary fibrosis.Nintedanib (BIBF 1120) for IPF: a tomorrow therapy?Idiopathic pulmonary fibrosis: early detection and referral.Recent evidence for pharmacological treatment of idiopathic pulmonary fibrosis.Exploring efficacy and safety of oral Pirfenidone for progressive, non-IPF lung fibrosis (RELIEF) - a randomized, double-blind, placebo-controlled, parallel group, multi-center, phase II trial.Where do we stand with IPF treatment?Mortality on the Waiting List for Lung Transplantation in Patients with Idiopathic Pulmonary Fibrosis: A Single-Centre Experience.Pirfenidone treatment in idiopathic pulmonary fibrosis: A Saudi experienceInhibitory effects of pirfenidone on dendritic cells and lung allograft rejection.Efficacy and adverse events of pirfenidone in treating idiopathic pulmonary fibrosis.Clinical highlights from the 2011 ERS Congress in Amsterdam.Idiopathic pulmonary fibrosis: pathogenesis and management.Treating idiopathic pulmonary fibrosis with the addition of co-trimoxazole: an economic evaluation alongside a randomised controlled trial.Treating idiopathic pulmonary fibrosis: current opportunities and future challenges.
P2860
Q26738458-68FB51DC-407A-47E3-AA3C-B64E14A996DFQ26771309-FA0CBA88-844D-49C8-BE6C-4ADE483C55C7Q26797272-22A943A2-4564-4983-88E3-6CB0CB98BB82Q26823161-54FD66E7-5B24-4645-B20D-F20B527D5AE4Q26849378-6CBAC8A5-8220-4311-B3D7-828CF3A95960Q28073641-3DDF6366-6309-415B-8EB7-61CEC2A5BCD6Q28083944-241A1FFA-0859-4EA6-8073-C8F72EA33861Q28389128-71AF4C5F-DAA3-4D33-A6DC-2FD2903560A4Q28484304-27E61072-E4D8-4394-8ED4-9C6116FB0A21Q30426516-49BFB31C-D6F8-4F74-92E0-06D75A81DAFFQ31030917-F4401CE4-AB40-44F6-8685-2C84A3270EA4Q33738931-DA8C94F3-5FDB-4BC9-AE81-ADABA4372DC8Q34503157-931CECD4-5C16-42E8-BF52-104B9D8A2A2FQ34734509-9C8CF424-2E57-456F-944F-48623A04FC59Q35892054-FF4C5F10-64F7-4DD3-A185-929B05469AFBQ36264068-92C78DFE-A769-478A-87BC-9F47588356E7Q36294959-222C8F6E-C325-40A1-9776-5E4BF6C61AD0Q36487876-53E858FA-E43C-4C99-9FBA-47DABF12B957Q36813946-60975199-D655-44A7-BB3A-B4790A31C441Q36814125-EABF5603-6196-4A68-BE0B-A5E5B0F8A761Q36850698-3F99DC0D-576D-4C26-BBC7-3E347E89D601Q37076998-097CFC7B-1A41-4F8F-B32F-492E5540895EQ37112937-0DA5C331-DBEC-47CF-9AE2-E62AEC6DD6DAQ37247255-55490D58-8DCE-44C2-8C30-64189E8A6967Q37592055-42E44DC4-F63E-4978-9ACF-0377C8329370Q37621515-124E78E3-16A0-4471-8311-EF3484224606Q38059265-0F465096-E24A-44E8-8E32-9F44EF84F7FBQ38205617-AAEF29F4-8A99-47A1-8F70-238AE0189F2AQ38247265-5F32CD08-72F4-4848-804A-634830DB06FFQ39150142-904D7B93-9A48-4FFF-A830-06333E33FFFAQ40351263-E244FE32-0045-4429-9040-E05C9E581DDEQ40689423-125D4148-FCA7-4933-97EF-CDC0E0986C04Q41910552-6EDA38E2-4506-4D9B-A58F-A691319B00C3Q42246110-462A1AFE-C815-42DC-8AC5-100E2C33E2E5Q42643913-1DDD7BFB-8AC4-4FB7-A17C-02B4BA17C936Q43187090-10A09D03-4114-458B-81DC-EA3D04028766Q50326794-F95B9C81-28EF-4EA3-941A-9EC2D6D60531Q50747284-36DFAAAE-DE19-42C6-976A-8B46DF5072ACQ51589237-69FBF273-5CCB-426B-9F9D-54A68AF093CD
P2860
description
2010 nî lūn-bûn
@nan
2010 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի սեպտեմբերին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
name
Non-steroid agents for idiopathic pulmonary fibrosis
@ast
Non-steroid agents for idiopathic pulmonary fibrosis
@en
Non-steroid agents for idiopathic pulmonary fibrosis
@en-gb
Non-steroid agents for idiopathic pulmonary fibrosis
@nl
type
label
Non-steroid agents for idiopathic pulmonary fibrosis
@ast
Non-steroid agents for idiopathic pulmonary fibrosis
@en
Non-steroid agents for idiopathic pulmonary fibrosis
@en-gb
Non-steroid agents for idiopathic pulmonary fibrosis
@nl
prefLabel
Non-steroid agents for idiopathic pulmonary fibrosis
@ast
Non-steroid agents for idiopathic pulmonary fibrosis
@en
Non-steroid agents for idiopathic pulmonary fibrosis
@en-gb
Non-steroid agents for idiopathic pulmonary fibrosis
@nl
P2093
P2860
P50
P3181
P1476
Non-steroid agents for idiopathic pulmonary fibrosis
@en
P2093
E. Haydn Walters
Fabrizio Luppi
Paolo Spagnolo
Sara Balduzzi
P2860
P304
P3181
P356
10.1002/14651858.CD003134.PUB2
P407
P577
2010-09-08T00:00:00Z